Healthcare Industry News:  Cook 

Devices Cardiology

 News Release - May 11, 2013

Landmark Study Demonstrates Lower Rate of Inappropriate Shocks in Patients with Sorin Dual Chamber ICD Devices

Late-breaking data presented at Heart Rhythm Society’s 2013 Annual Meeting show benefits compared with single chamber devices sustained in long-term follow up

DENVER--(Healthcare Sales & Marketing Network)--Sorin Group (SRN.MI), a global medical company and a leader in the treatment of cardiovascular diseases, announced findings from the landmark OPTION study1 demonstrating that patients with Sorin dual-chamber implantable cardioverter defibrillators (ICDs) experienced a significantly lower incidence of inappropriate shocks compared with patients with standard single-chamber devices (4.3% vs.10.3%, p=0.015).The study also found that there was no difference in all-cause mortality between the two groups.

The OPTION study results were presented as a late-breaking clinical trial at the Heart Rhythm Society’s 2013 Annual Scientific Meeting in Denver, Colorado, from May 8 - 11.

A total of 462 patients at 54 centers in Europe and North America were enrolled in the study. Patients were randomized to either dual-chamber or standard single-chamber ICD therapy. Study endpoints were the occurrence of appropriate and inappropriate shocks and all-cause mortality. Median follow up was over two years.

The OPTION study demonstrates the benefits of Sorin dual-chamber ICD therapy. Sorin dual-chamber ICDs feature the PARAD+™ arrhythmia discrimination algorithm which reduces the number of inappropriate shocks2, and the SafeR™ pacing mode which minimizes unnecessary ventricular pacing.3 Excessive right ventricular pacing has been associated with dual chamber pacing and has been shown to increase heart failure and atrial fibrillation.4,5

“This is very good news for patients. We have known for a long time that inappropriate shocks were associated with poor quality of life and adverse outcomes,” said, Dr. Christof Kolb of the DeutschesHerzzentrum Munich, Germany, and principal study investigator. “The findings demonstrate that patients can rest assured that their Sorin ICD is correctly monitoring their heart and delivering only the therapy that is needed.”

While ICDs deliver lifesaving therapy to patients at risk of sudden cardiac arrest, inappropriate shocks still occur too frequently and negatively impact patients’ quality of life. ICDs are available in single and dual-chamber models and use differing methods to detect a patient’s arrhythmias and treat them with antitachycardia therapies; both types of ICDs can provide rescue shocks. Many physicians consider that dual-chamber ICDs provide superior antitachycardia therapy compared with single-chamber devices, but long-term data were lacking.

“The results of the OPTION study fill an evidence gap,” said Dr. Dan Dan, Piedmont Heart Institute, Atlanta, GA. “We always thought that dual-chamber ICDs which preserve the natural cardiac conduction, were a better choice for our patients. This has been proven in this well-designed study,” he said.

“Sorin is committed to developing technologically advanced devices that provide smart therapies that are both lifesaving and beneficial to physicians and patients alike. We continue to invest in advancing knowledge about cardiac rhythm disorders and will support clinical trials that provide the strongest possible evidence supporting our therapies,” said Stefano Di Lullo, President, CRM Business Unit, Sorin Group.

About Sorin Group

Sorin Group ( is a global, medical device company and a leader in the treatment of cardiovascular diseases. The Company develops, manufactures, and markets medical technologies for cardiac surgery and for the treatment of cardiac rhythm disorders. With 3,750 employees worldwide, the Company focuses on two major therapeutic areas: Cardiac Surgery (cardiopulmonary products for open heart surgery and heart valve repair or replacement products) and Cardiac Rhythm Management (pacemakers, defibrillators and non invasive monitoring to diagnose and deliver anti-arrhythmia therapies as well as cardiac resynchronization devices for heart failure treatment). Every year, over one million patients are treated with Sorin Group devices in more than 80 countries.

For more information, please visit

1. Kolb C, Babuty D, Sick P, et al. Lower occurrence of inappropriate shock in dual chamber ICD therapy reached with optimized discrimination and minimized Vp. Presented at: 34th Annual Scientific Sessions of the Heart Rhythm Society, May 8-11, 2013, Denver, CO, USA.

2. Anselme F, Mletzko R, Bowes R, et al. Prevention of inappropriate shocks in ICD recipients: a review of 10,000 tachycardia episodes. PACE. 2007;30S128-S133. Study made using dual-chamber ICDs with standard dual-chamber arrhythmia classification algorithms.

3. Davy JM, Hoffmann E, Frey A, et al. Near elimination of ventricular paving in SafeR mode compared to DDD modes: a randomized study of 422 patients. Pacing Clin Electrophysiol. 2012;35(4):392-402.

4. Sweeney MO, Hellkamp AS, Ellenbogen KA, et al. Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. Circulation. 2003;107:2932-2937.

5. Wilkoff BL, Cook JR, Epstein AE, et al. Dual chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the dual chamber and VVI implantable defibrilaltor (DAVID) trial. JAMA 2002; 288:3115-23.

Source: Sorin Group

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps 2 - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps 2 - available on the Apple App Store for iPhone and iPad.